Meeting
2023 ASCO Genitourinary Cancers Symposium
Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Louise Kathleen Kostos
Department of Medical Oncology, Peter MacCallum Cancer Centre; and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
Louise Kathleen Kostos , William Yu Ching Lai , Peter Lambroglou , Elizabeth Medhurst , James Patrick Buteau , Shahneen Sandhu , Ben Tran , Lavinia Anne Spain , Ciara Conduit , Roslyn Wallace , Ramin Alipour , Timothy J. Akhurst , Grace Kong , Anthony Cardin , Javad Saghebi , Aravind Ravi Kumar , Michael S Hofman , Arun Azad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 77)
DOI
10.1200/JCO.2023.41.6_suppl.77
Abstract #
77
Poster Bd #
C7
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
First Author: Pedro C. Barata
Poster
2012 ASCO Annual Meeting
Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
First Author: Mario A. Eisenberger
First Author: Elena Castro
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova